It was demonstrated that this immunotherapeutic approach provides significant results: efficient tumor-specific CTLs are activated and protective immunity is triggered in mice with HER2/Neu+ Tg1-1 breast cancer or HLA-A2+HER2+ B16-F10 melanoma. The gene discussed is ERBB2; the disease is neoplasm.